Karyopharm Therapeutics Inc.
KPTI
$1.62
-$0.08-4.44%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -4.66% | 2.90% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -4.66% | 2.90% | |||
| Cost of Revenue | -14.51% | 20.55% | |||
| Gross Profit | 4,560.53% | -101.54% | |||
| SG&A Expenses | -2.88% | 17.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.49% | 19.07% | |||
| Operating Income | 15.82% | -49.97% | |||
| Income Before Tax | -199.33% | 78.10% | |||
| Income Tax Expenses | -- | 101.49% | |||
| Earnings from Continuing Operations | -199.32% | 78.09% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -199.32% | 78.09% | |||
| EBIT | 15.82% | -49.97% | |||
| EBITDA | 15.80% | -50.06% | |||
| EPS Basic | -127.69% | 82.18% | |||
| Normalized Basic EPS | -127.72% | 54.36% | |||
| EPS Diluted | -87.69% | 78.35% | |||
| Normalized Diluted EPS | -155.67% | 59.35% | |||
| Average Basic Shares Outstanding | 31.45% | 22.96% | |||
| Average Diluted Shares Outstanding | 17.09% | 38.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||